Targeted alpha-particle therapy (IMAGE)
Caption
A schematic of the study. The simple targeted alpha-particle therapy (TAT) compound was made by joining the radionuclide astatine-211 to an azide. The TAT compound was injected into a mice that had human lung cancer implants. The TAT targets acrolein, which is abundant in cancer cells, but not in healthy cells. After reacting with acrolein, the compound becomes anchored to an organelle in the cell, and when alpha particles are released, they damage it.
Credit
RIKEN
Usage Restrictions
credit RIKEN
License
Original content